Salvage treatment of relapsed/refractory LCH - Wikidata - wikimedia - TriplyDB

Salvage treatment of relapsed/refractory LCH

Salvage treatment of relapsed/refractory LCH

http://www.wikidata.org/entity/Q42195584

about

Salvage treatment of relapsed/refractory LCH

http://www.wikidata.org/entity/Q42195584

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Salvage treatment of relapsed/refractory LCH

@en

Salvage treatment of relapsed/refractory LCH

@nl

type

label

Salvage treatment of relapsed/refractory LCH

@en

Salvage treatment of relapsed/refractory LCH

@nl

prefLabel

Salvage treatment of relapsed/refractory LCH

@en

Salvage treatment of relapsed/refractory LCH

@nl

P1433

Q42195584-9039A16F-60AC-49DB-A0BA-150D1579186E

P1476

Q42195584-5B435099-F76F-4845-99A8-7567EDD9B450

P2093

Q42195584-ADF395E3-DE79-464E-AFBB-34BF1A70F7D3

P2860

Q42195584-0F110519-5C39-4F7F-AD16-B05745A65F85

Q42195584-15EFD801-1ECC-4C4F-AD82-EF330FE28055

Q42195584-26EE92B5-273B-4546-B054-4D1B06160FD9

Q42195584-4D0518EF-DFAC-4115-9F98-AD1EEEB81607

Q42195584-5B5A1DC9-ADDF-45C3-97CF-5AC38547F752

Q42195584-90A0D67E-D957-470B-AC06-807B3440C60B

Q42195584-96720C26-A7A7-4CBD-9C89-D2AEF8A1EE46

Q42195584-977B4A07-1E4A-4F96-902B-E74CBFC12F70

Q42195584-D5E909A0-D472-419A-B01B-30B4E7E41104

Q42195584-FF129822-7E71-40C6-8930-DC201FBE582C

P304

Q42195584-4B3342DE-60F5-4A20-82A7-1CF34A60AF97

P31

Q42195584-B408A562-DB67-4B3A-9769-70311F4054C4

P356

Q42195584-4D8636D7-471A-4ED9-B81C-EFAA6E633756

P433

Q42195584-BB245BE9-65A5-497A-9E29-AEDB3466C25D

P478

Q42195584-D7690823-E203-494B-901F-DE351DA0636B

P577

Q42195584-DD466739-4323-4470-9B25-EA9FDA7C00D9

P698

Q42195584-82A6D350-FC88-4598-B467-933924BEFA65

P932

Q42195584-FB54AC87-1054-4838-B7F4-AF5AEC81A801

P356

BR.2016.51.4.220

P1433

P1476

Salvage treatment of relapsed/refractory LCH

@en

P2093

Jong Jin Seo

http://www.w3.org/2001/XMLSchema#string

P2860

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.

Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning.

Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.

How I treat Langerhans cell histiocytosis.

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis.

Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age.

Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children.

P304

220-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5045/BR.2016.51.4.220

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28090481

http://www.w3.org/2001/XMLSchema#string

P932

5234242

http://www.w3.org/2001/XMLSchema#string